Loading clinical trials...
Loading clinical trials...
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study
Conditions
Interventions
Favipiravir Combined With Tocilizumab
Favipiravir
+1 more
Locations
6
China
Guiqiang Wang
Beijing, Beijing Municipality, China
Peking University First Hospital
Beijing, Beijing Municipality, China
Ezhou Central Hospital
Wuhan, Hubei, China
Huoshenshan Hospital of Wuhan
Wuhan, Hubei, China
Jinyintan Hospital of Wuhan
Wuhan, Hubei, China
Wuhan Pulmonary Hospital
Wuhan, Hubei, China
Start Date
March 8, 2020
Primary Completion Date
May 1, 2020
Completion Date
May 1, 2020
Last Updated
April 10, 2020
NCT07221162
NCT06082518
NCT06631287
NCT06679140
NCT06417762
NCT03830320
Lead Sponsor
Peking University First Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions